Prerpints.org logo
Preprint
Review

The Role of Pulmonary Collectins, Surfactant Protein A (SP-A) and Surfactant Protein D (SP-D) in Cancer

This version is not peer-reviewed.

Submitted:

26 July 2024

Posted:

27 July 2024

You are already at the latest version

A peer-reviewed article of this preprint also exists.

Abstract
Surfactant proteins A and D (SP-A and SP-D) belong to the collectin subfamily of C-type oligomeric lectins. They are pattern-recognition molecules (PRM), able to recognise pathogen- or dan-ger-associated molecular patterns (PAMP, DAMP) in the presence of Ca2+ cations. That property enables opsonisation or agglutination of non-self or altered/abnormal self-cells, and contributes to their clearance. Like other collectins, SP-A and SP-D are characterised by the presence of four distinct domains: a cysteine-rich domain (at N-terminus), a collagen-like region, an α-helical neck domain and a globular carbohydrate-recognition domain (CRD) (at C-terminus). Pulmonary sur-factant is a lipoprotein complex, preventing alveolar collapse by reducing surface tension at the air-liquid interface. SP-A and SP-D, produced by type II alveolar epithelial cells, and Clara cells, are not only pattern-recognition molecules but also contribute to the surfactant structure and homeo-stasis. Moreover, they are expressed in a variety of extrapulmonary sites where they are involved in local immunity. The term “cancer” includes a variety of diseases: tumours start from uncontrolled growth of abnormal cells in any tissue which may further spread to other sites of the body. Many cancers are incurable, difficult to diagnose and often fatal. This short review summarises anti- and pro-tumourigenic associations of SP-A and SP-D as well as perspectives of their usefulness in cancer diagnosis and therapy.
Keywords: 
cancer
;  
collectin
;  
pulmonary surfactant
;  
surfactant protein A (SP-A)
;  
surfactant protein D (SP-D)
Subject: 
Biology and Life Sciences  -   Immunology and Microbiology

1. The Collectin Subfamily

The human collectin subfamily of C-type lectins includes six oligomeric pattern-recognition molecules (PRM): mannose-binding lectin (MBL) (also called mannan-binding lectin), collectin-10 (CL-10) (or collectin-liver 1, CL-L1), collectin-11 (CL-11) (or collectin-kidney 1, CL-K1), collectin-12 (CL-12) (or collectin-placenta 1, CL-P1), surfactant protein A (SP-A) and surfactant protein D (SP-D) (reviewed in [1,2]). They recognise pathogen- or danger-associated molecular patterns (PAMP, DAMP) in the presence of Ca2+ cations, enabling opsonisation or agglutination of non-self or altered/abnormal self-cells, and contributing to their clearance. Moreover, MBL, CL-10, CL-11 and CL-12 are able to activate complement, extending the range of their participation in the immune response while SP-A and SP-D lack this property [1,2]. In general, the basic subunit of collectin molecules consists of three, usually identical chains. However heterotrimers built up from CL-10 and CL-11 (their higher oligomer is called CL-LK) or two different SP-A polypeptides (discussed below) are not uncommon. Those subunits undergo further oligomerisation, forming dimers, trimers, tetramers or hexamers of basic triplets. That enables strengthening of ligand binding capacity which is relatively low for a single CRD [1,2]. Collectins are characterised by the presence of four distinct domains: a cysteine-rich domain (at N-terminus), a collagen-like region, an α-helical neck domain and a globular carbohydrate-recognition domain (CRD) (at C-terminus). The collagenous domain includes Gly-X-Y repeats (where X and Y correspond to any amino acid residues) [1,2]. Figure 1 demonstrates structure of SP-A and SP-D as well as organisation of corresponding genes.

2. Pulmonary Surfactant Collectins: SP-A and SP-D

Pulmonary surfactant is a lipoprotein complex, preventing alveolar collapse by reducing surface tension at the air-liquid interface. Proteins constitute approximately 10% of the complex. Two hydrophobic proteins, SP-B and SP-C are involved in controlling surface tension and stabilisation of the surfactant. Furthermore, the latter is considered to influence the innate immune response, due to its ability to bind bacterial lipopolysaccharide (LPS, endotoxin). Hydrophilic collectins, SP-A and SP-D, produced by type II alveolar epithelial cells, and Clara cells, are not only pattern-recognition molecules but also contribute to the surfactant structure and homeostasis (reviewed in [3]). Two other surfactant proteins, SP-G (or surfactant-associated protein 2, SFTA2) and SP-H (or SFTA3), although structurally different, have physicochemical properties resembling SP-B and SP-C (reviewed in [4]).
As mentioned, human pulmonary surfactant protein A has two distinct forms, called SP-A1 and SP-A2 which may form homo- or heterotrimeric subunits. Despite high similarity, they are encoded by separate genes (SFTPA1 and SFTPA2), each encompassing six exons, being in linkage disequilibrium. They are localised to chromosome 10 (10q21-24), in opposite transcriptional orientation. Both SFTPA1 and SFTPA2 are highly polymorphic. Their variants called 6A, 6A2, 6A3, 6A4, 6A5 or 1A, 1A0, 1A1, 1A2, 1A3, 1A5, respectively, corresponding to fourteen single nucleotide polymorphisms (SNP) have been established (for details see Figure 2) and commonly used in analyses concerning SP-A clinical associations (reviewed in [2,3,5]). Since two SNP (within codons 9 and 19) affect sequences of signal peptides but not structures of mature protein (Figure 2), expression of certain pairs of genetic variants [6A-6A3 (SFTPA1); 1A-1A5, 1A0-1A2, 1A1-1A3 (SFTPA2)] results in synthesis of identical products [6]. The 35 kDa polypeptide chains of both SP-A1 and SP-A2 consist of 248 AA (Figure 1). That collectin recognises PAMP/DAMP containing residues of such monosaccharides as N-acetyl-D-mannosamine (D-ManNAc), D-mannose (D-Man), L-fucose (L-Fuc), D-maltose (D-Mal), D-glucose (D-Glc) or N-acetyl-D-glucosamine (D-Glc-NAc) and other compounds, like galactosyl-ceramide, lactosyl-ceramide and nucleic acids [1,2,4,6,7,8].
The SFTPD (SP-D) gene, encompassing eight exons, is also localised to chromosome 10 (10q21-24). Like those encoding SP-A, it is highly polymorphic. Some SFTPD SNP, located in exons are related to amino acid exchanges [rs721917 (+32 T>C, M11T), rs2243639 (+478 A>G, T160A), rs3088308 (+868 T>A, S270T)], several others are associated with modifications of nucleotide sequence only [rs6413520 (+75 T>C, S25S), rs1051246 (+858 T>C, A286A)] [3,9,10]. Those mentioned (and some other) SFTPD polymorphisms are considered clinically relevant. This review is however limited to their associations with cancer, discussed below.
The SP-D polypeptide chain (43 kDa) is composed of 355 amino acid residues (Figure 1). Basic trimers oligomerise into dodecamers (tetramers of subunits) which may further multimerise (up to 96 single chains). The carbohydrate-recognition domain of this collectin has affinity for the majority of sugars being recognised by SP-A (D-Mal, D-Man, L-Fuc, D-GlcNAc, D-Glc) but also recognises D-galactose (D-Gal), lactose (disaccharide), phosphatidylinositol, glucosyl-ceramide, DNA and RNA [2,4,6,8,11,12].
Pulmonary surfactant collectins are important components of the innate immune system, crucial for protection of the respiratory system from pathogens or allergens. Moreover, they are also expressed in a variety of extrapulmonary sites where they are involved in local immunity. Both SP-A and SP-D have been detected (at various levels) in brain, gastrointestinal system, skin, salivary glands, eye and lacrimal system, Eustachian tube, thymus, kidney, ureter, bladder, testis, prostate, mammary glands, uterus, vagina, amniotic epithelium and placenta. Furthermore, SP-D can be found in heart, trachea, ovary, fallopian tube and blood (reviewed in [4,13,14]). SP-A and SP-D act as chemoattractants for macrophages, promote phagocytosis, stimulate the production of pro- and anti-inflammatory cytokines and interact with antigen-presenting cells and T-lymphocytes. Importantly, despite clearance of pathogens/allergens, pulmonary collectins contribute to removal of apoptotic cells via promoting their phagocytosis and then to preventing adverse effects of their accumulation [3,14].

3. The Role of SP-A and SP-D in Cancer

3.1. Lung Cancers

Most reports concerning associations of pulmonary surfactant collectins with malignancies relate to lung cancer. Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-associated mortality (causing approx. as many deaths as colorectal, breast and prostate cancers together) [15,16,17,18,19]. In 2022, nearly 2.5 million new cases were diagnosed globally (12.4% of all cancers) and 1.8 million deaths were noted (18.7%) [19]. This high mortality is a reflection of difficulty of early diagnosis, high metastatic potential and often poor response to therapy [20,21]. Most tumours are classified as non-small cell lung cancer (NSCLC, >80% cases), and include adenocarcinomas, squamous cell carcinomas and large-cell carcinomas. The remaining <20% are small-cell lung carcinomas [17].
Kaczmarek et al. [22] found higher SP-A concentrations in malignant (from patients diagnosed with non-small cell lung cancer), compared with non-malignant pleural effusions. Levels of this collectin in malignant samples correlated positively with stem cell factor (SCF) but inversely with macrophage colony-stimulating factor (M-CSF). High SP-A levels were accompanied by an increase in the number of M2 macrophages and a decrease in the number of M1 macrophages [22]. Earlier, high SP-A concentrations were observed in pleural effusions from approx. 40% patients suffering from pulmonary adenocarcinoma but not from those diagnosed with other adenocarcinomas, other lung cancers or tuberculosis [23]. The same group suggested high SP-A and carcinoembryonic antigen (CEA) concentrations in pleural effusions to distinguish between lung adenocarcinoma and mesothelioma [24]. Takezawa et al. [25], with the use of immunostaining or RT-PCR, evidenced expression of SP-A in cells present in pleural effusions from the majority of patients suffering from primary lung adenocarcinoma. Using immunohistochemistry, this collectin was also found in primary pulmonary adenocarcinoma cells inside tumours [17,26,27,28,29,30,31,32,33,34] and, like in pleural effusions, proposed to be useful for discrimination of that disease from mesothelioma [29]. A high ratio of MUC1 mucin/SP-A expression appeared to predict a fatal outcome in patients diagnosed with small-size tumours [31]. Liu et al. [34] found no association of SP-A status with patient’s age, tumour differentiation or disease stage, but positive immunostaining was more frequent among patients with confirmed mutations of the EGFR (HER1) gene (characteristic for some cancers, including pulmonary adenocarcinomas, especially in female non-smoking Euro-Asian patients), encoding for epidermal growth factor receptor [34]. Linnoila et al. [26] found the highest frequency (50%) of positive staining in adenocarcinomas of papillolepidic growth patterns and lower in other adenocarcinomas and other non-small cell lung cancers. Although Suzuki et al. [32] observed no SP-A staining in other primary lung carcinomas or adenocarcinomas of other organs, they suggested napsin A (an aspartic protease, involved in pro-SP-B processing) to be a better disease marker. Furthermore, Zamecnik and Kodet [30] found small cell lung carcinomas, squamous cell carcinomas and carcinoid tumours SP-A to be negative, in contrast to 46% of adenocarcinomas and 25% of non-neuroendocrine large cell carcinomas, and suggested that SP-A immunostaining does not improve the diagnostic usefulness of thyroid transcription factor-1 (TTF-1). SP-D was in turn suggested to be useful as a marker of risk of early lung cancer in smokers and ex-smokers: its low concentration in bronchoalveolar lavage fluid (BALF) was found associated with progression of bronchial dysplasia [35]. Later, Yamaguchi et al. [36] found a significant relationship between high SP-D concentration in serum before therapy and longer progression-free survival in patients suffering from advanced non-small lung cell carcinomas, treated with gefitinib. No such association was observed for SP-A [36]. Moreover, high SP-D level was reported to be associated with a lower number of distinct metastases and to predict longer progression-free survival and overall survival in patients with lung adenocarcinoma with EGFR mutations, treated with tyrosine kinase inhibitor (TKI) [37], as well as overall survival in patients with NSCL undergoing stereotactic body radiotherapy [38]. On the other hand, Takahashi et al. [39] found higher concentrations of both SP-A and SP-D in sera from patients suffering from lung cancers who developed radiation pneumonitis (RP), in comparison with those without RP. Similarly, higher median SP-D was observed by Shiels et al. [40], in patients of various ethnicity (mainly Caucasian) compared with controls. High (4th quartile) levels of this collectin were found to be a risk factor for developing disease [40]. Interestingly, SP-D and SP-A are able to supress EGFR-mediated signalling via different mechanisms. SP-D binds the EGFR due to recognition of oligomannose type N-glycans by the lectin domain (CRD) (inhibitable by EDTA), while SP-A interacts with that receptor electrostatically [41,42].
Expression of SP-A at the mRNA level in primary lung adenocarcinoma cells was reported by Broers et al. [43] and Takahashi et al. [44]. Furthermore, SP-A- (as well as SP-C)-specific mRNA was also detected in peripheral blood of 1/3 primary NSCLC patients. It was suggested that their presence indicated a high risk of metastasis. Indeed, Betz et al. [45] observed SP-A and SP-C mRNA expression in metastatic pulmonary adenocarcinomas but not metastatic NSLC or extrapulmonary adenocarcinomas. No SP-A expression was found among cases of small cell lung cancer, secondary lung tumours or non-malignant respiratory diseases [20].
Wang et al. [46] claimed two SFTPA2 gene polymorphisms, T593C (F198S) and G692T (G231V), were associated with lung adenocarcinoma. The corresponding variant alleles lead to a change of structure in the SP-A2 lectin domain and therefore may affect its ability to recognise molecular patterns. Although SP-A was detectable in tumour cells from heterozygous patients, transfection of A549 cells with any of mutated SFTPA2 variants revealed poor protein expression, in contrast to the cells transfected with wild-type gene. It was speculated that impaired SP-A2 synthesis may lead to an imbalance of immunoregulation and result in pulmonary fibrosis or cancer [46]. The significance of SP-A polymorphisms affecting CRD structure/function, was further explored in studies of familial interstitial lung diseases and cancer. The G532A (V178M), T631C (W211R), C655T (R219W) single nucleotide (amino acid) exchanges in the SFTPA1 and T697A (W233R), G699C (W233C) and G713C (C238S) in the SFTPA2 genes were associated with lung tumours in families of various ethnicity [47,48]. For the SFTPD gene, variant alleles for T32C (M11T) and intronic rs2245121 (G>A) were reported to be risk factors in Japanese and Chinese (smokers) populations [49,50]. Moreover, Grageda et al. [51] found lower SFTPA2 mRNA/protein expression in pulmonary squamous cell carcinoma and adenocarcinoma, accompanied by higher DNA methylation of the gene promoter in the former. Earlier, an association of hypermethylation of the SFTPA1 (at SP-A1_370 and SP-A1_1080 CpG sites) and SFTPD (SP-D_1170 and SP-D_1370) with cancers of the same types was reported by Lin et al. [52]. Jiang et al. [53,54], investigating genomic profiles of patients diagnosed with stage I primary NSCLC, found some aberrations (including SP-A deletion), possibly associated with tumourigenesis and potentially useful as disease markers. Using fluorescence in situ hybridisation (FISH), they found ≤3% cells presenting loss of SP-A signals in normal lung tissues. In 25/28 tumour specimens, the lack of corresponding signal was observed in >6% cells. Importantly, that occurred significantly more often in samples from smokers compared with never-smokers. Moreover, SP-A deletions (and especially their high rate) predicted shorter survival time. It was suggested also that the SP-A copy number may be helpful in predicting appropriateness and effectiveness of adjuvant therapy [54]. Interestingly, Linnoila et al. [26] reported that SP-A protein detection in tumour tissue sections was associated with lighter smoking history.
More evidence concerning surfactant protein A in pulmonary cancer has been provided by Mitsuhashi et al. [21], who using human lung adenocarcinoma (PC14PE6, A549) lines transduced with the SFTPA1 gene, demonstrated suppression of tumour progression in a murine model of subcutaneous xenograft or lung metastasis. They noticed a higher number of M1 type (M2 type unchanged) macrophages in tumours related to SP-A-synthesizing cells, compared with control. The number of natural killer cells was higher as well. It was suggested that SP-A induces polarization of tumour-associated macrophages contributing to NK recruitment and activation, and finally, to the inhibition of tumour growth [21]. Recently, in silico analysis revealed in turn that low SFTPD gene expression is correlated with alectinib resistance and may predict poor prognosis in patients suffering from lung adenocarcinoma. An association of low SP-D expression and drug resistance was further confirmed experimentally (RT-PCR) with the use of the adenocarcinoma H3122 cell line and its alectinib-resistant counterpart H3122R [55]. That is in agreement with an earlier report published by Mangogna et al. [56], who, using OncomineTM platform, noted lower SFTPD mRNA level in lung cancers compared with normal tissue. They moreover suggested that SP-D expression in adenocarcinoma and squamous cell carcinoma tissues may correlate with overall survival rate and therefore may be associated with a favourable prognosis. It was however in general lower in cancerous compared with normal tissue, as demonstrated with the use of immunohistochemistry [56].

3.2. Cancers of Other Organs

Much less data have been collected and published with regard to the role of pulmonary collectins in primary tumours localised outside the respiratory system. Most of those reports have been focused on reproductive or digestive systems.
According to recent statistics, provided by the Global Cancer Observatory (GLOBOCAN), prostate cancer is the fourth most common cancer (nearly 1.5 million new cases in 2022 worldwide) and the eighth most deadly one (almost 0.4 million deaths) (7.3% and 4.1%, respectively) [19]. Most are adenocarcinomas. Expression of both SP-A and SP-D in human prostate was noted in several studies [57,58,59,60,61,62]. Kankavi et al. [63], using immunohistochemistry, found lower SP-A and SP-D staining in prostate adenocarcinoma tissue sections compared with non-malignant tissue. They moreover reported lower expression of both collectins in relation to higher Gleason score, tumour volume and age of patients. Very weak or no staining corresponded to Gleason score ≥7. Those findings suggested that pulmonary collectins may be considered as disease markers [63]. Later, Thakur et al. [64] found lower SFTPD mRNA and SP-D protein in cells of the androgen-dependent prostate cancer LNCaP line, compared not only with primary prostate epithelial cells but also with androgen-independent lines (PC3 and DU145). Furthermore, with the help of TRAMP (transgenic adenocarcinoma of mouse prostate) model, increased degradation of SP-D (suspectedly via serine proteases synthesized by granulocytes and polymorphonuclear myeloid-derived suppressor cells) in advanced disease stage was evidenced [65]. Interestingly, a recombinant fragment of human SP-D (rfhSP-D, a trimer of chains consisting of CRD, neck domain and eight Gly-X-Y triplets) induced apoptosis of cells of both androgen-dependent (LNCaP, p53-wild type) and -independent (PC3, p53-mutated) lines, explants and primary tumour cells from metastatic patients [64] as well as TRAMP explants [65], suggesting therapeutic potential of that collectin. A 78 kDa glucose-regulated protein (GRP78) was identified as a ligand for the SP-D lectin domain in androgen-independent metastatic prostate cancer cells (PC3 line), based on interactome and docking analysis. Furthermore, recombinant GRP78 was shown to inhibit binding of CRD-specific anti-SP-D antibody to the recombinant (complete molecule) collectin [66].
Testicular cancer is less common than prostate cancer (although >72 000 new cases and approx. 9 000 deaths were noted in 2022) [19], but is the commonest tumour among men aged <40 years [62]. SP-A and SP-D (as well as SP-B and SP-C) expression was demonstrated in normal, peritumoural and tumoural testis. Although there was no greater difference in the case of mRNA related to pulmonary collectins, the protein levels (especially SP-D in samples from seminoma patients) were generally lower in cancer cases [62].
The second most common malignancy worldwide (and the commonest in women but rare in men) is breast cancer (>2.3 million females newly diagnosed, nearly >665 000 died in 2022) [19]. Its most common types include ductal breast carcinoma (in situ or invasive) and lobular carcinoma (in situ or invasive). Based on bioinformatics analysis (OncomineTM platform), Mangogna et al. [56] demonstrated lower SFTPD gene-related mRNA expression in invasive ductal breast carcinoma, male breast carcinoma and breast phyllodes tumour than in normal breast tissue samples. However, high SP-D expression was associated with shorter overall survival in patients with Luminal-A grade-1 and -2 breast cancers [56]. Like prostate cancer, SP-D may act pro-apoptotically on some breast tumour cells. Afore-mentioned rfhSP-D was demonstrated to induce cell death in HER2 receptor-over-expressing SKBR3, triple-positive (HER2, oestrogen, progesterone) BT474 lines. That activity was however inhibited efficiently in the presence of hyaluronic acid (promoting breast cancer progression and invasion when increased in the tumour microenvironment). Moreover, no pro-apoptotic effect was noted in the case of triple-negative cells of the BT20 line [67].
Ovarian cancer (OC), although much less common, is one of the most deadly tumours among women (>324 000 new cases, almost 207 000 deaths in 2022) [19]. The most frequent serous ovarian adenocarcinoma belongs to the epithelial OC type. The presence of SP-D in human ovaries was originally reported by Oberley et al. [68].
In above-cited paper, a higher SFTPD mRNA expression in ovarian cancer (serous adenocarcinoma), compared with normal ovarian tissue was reported [56]. They confirmed that message experimentally, at both mRNA and protein levels. Additionally, more SP-D-expressing cells were found in the tumour microenvironment than in normal tissue (Mangogna et al., 2018). Later, based on OncomineTM as well, Kumar et al. [69] described SP-D-specific mRNA expressed not only in serous ovarian adenocarcinoma but also in mucinous, clear cell and endometrioid type tissues, independently of grade or stage. Although, generally, there was no significant difference in the expression levels in tumour compared with normal tissue, high SFTPD mRNA in cases predicted shorter overall and progression-free survival. Immunohistochemistry confirmed in silico data: SP-D protein was detected in serous papillary, mucinous and endometrioid cystadenocarcinoma samples. There was no significant differences depending on tumour grade (1-3), however high SP-D expression was over-represented among stage II compared with stage I samples. Moreover, low SP-D predicted better prognosis in patients at stages I-II but not III-IV. The protein appeared detectable not only in tissue sections (immunohistochemistry) but also in circulating tumour cells [69]. Importantly, like the TRAMP model, a recombinant fragment of human SP-D induced cancerous cell death, as evidenced with the use of SKOV-3 line. It furthermore impaired SKOV-3 cells migratory capacity and affected mTOR (mechanistic target of rapamycin) signalling (via down-regulation of Rictor and Raptor, constituents of mTORC1/mTORC2 complexes), associated with ovarian cancer progression [69]. Those data were further confirmed and extended with the use of rfhSP-D immobilised on carbon nanotubes (CNT) which inhibited Rictor and Raptor expression and induced synthesis of proinflammatory cytokines (IL-1β, TNF-α, TGF-β, GM-CSF) in SKOV-3 culture [70]. Altogether, data presented by Kumar et al. [69] and Alshaya et al. [70] again suggested the usability of SP-D as disease marker and/or its recombinant fragment as therapeutic agent.
Several associations of SP-D with gastrointestinal malignancies have been published. Colorectal cancer is the third most common and the second most lethal human cancer (over 1.9 million newly diagnosed cases, over 0.9 million deaths worldwide in 2022) [19]. Its most frequent type is adenocarcinoma. Although, to our knowledge, no papers concerning clinical material are available to date, some interesting data have been provided from a murine model. Tajima et al. [71], using the CMT93 (mouse rectal carcinoma) cell line demonstrated significantly higher susceptibility of SP-D-knockout mice to developing pulmonary metastases, compared to the wild-type animals. Furthermore, the ability of murine recombinant SP-D to suppress proliferation, migration and invasiveness of CMT93 cells was demonstrated [71].
Gastric cancer [almost 970 000 new cases (mostly adenocarcinomas), almost 660 000 fatal outcomes in 2022] is the fifth most common and deadly tumour [19]. Mangogna et al. [56], based on bioinformatics analysis, reported lower SFTPD mRNA expression in cancerous gastric mucosa (intestinal, diffuse and mixed type adenocarcinomas), compared with healthy tissue. A high level of SP-D expression predicted shorter overall survival in HER2-negative patients suffering from intestinal type adenocarcinoma, without distant metastases [56].
Less common (>510 000 new cases in 2022 worldwide, twelfth in frequency) but relatively more fatal (nearly 470 000 deaths, sixth most deadly) is pancreatic cancer [19]. Depending on type of cells undergoing transformation, exocrine (including most common adenocarcinomas) and endocrine tumours may be diagnosed. As in the case of several other diseases discussed above, some promising data have been published, concerning the therapeutic potential of a SP-D recombinant fragment. Kaur et al. [72] demonstrated a pro-apoptotic activity of rfhSP-D against pancreatic cancer cells, independently of their p53 status – namely, that product induced cell death via Fas-mediated pathway in Panc-1, MiaPaCa-2 (both aggressive, p53-mutated) as well as Capan-2 (non-aggressive, p53-wild type) cells. Importantly, a stronger effect was observed in the case of aggressive cells. The same authors evidenced ability of rfhSP-D to suppress epithelial-to-mesenchymal transition (EMT) of the mentioned cells. Down-regulation of TGF-β as well as mesenchymal markers (vimentin, ZEB1 and Snail) was demonstrated [73].
Regarding cancers outside the reproductive or digestive systems, higher SP-A (as well as SP-C) concentrations were found in BALF samples from children suffering from various types of haematologic malignancies (mostly diagnosed with acute myeloid leukaemia or acute lymphocytic leukaemia) and immunosuppression during therapy, compared with controls. The difference appeared particularly significant in the case of patients with proven presence of pathogens in their material. Therefore, up-regulation of SP-A may be associated with both response to cancer and to infection. No differences in SP-D levels were found [74]. Later, Mahajan et al. [75,76] reported induction of p53-dependent apoptosis of AML.14.3D10 cells of eosinophilic leukaemia line by SP-D (derived from amniotic fluid) and its recombinant fragment.

4. Concluding Remarks

Surfactant collectins as components of pulmonary surfactant and factors of innate immunity are important for maintaining homeostasis. Based on literature cited here, it may however be stated that even though they generally act as Dr Jekyll, under certain circumstances they may play the role of Mr Hyde, when their high expression is associated with disease itself or predicts poor prognosis. Their widely-understood relationships with cancer include a contribution to elimination of some carcinogenic pathogens. Finally, in some cancers, they may be considered promising diagnostic/prognostic markers, therapeutic agents or therapeutic targets. The recombinant SP-D fragment (rfhSP-D), has been shown to induce apoptosis of a variety of tumour cells, and seems especially hopeful for development of future therapies.

Author Contributions

AŚ and MC both conceived the idea for the review, collected and selected literature to be included. MC wrote draft manuscript. AŚ reviewed the draft version, MC prepared the submitted version. Both authors have read and agreed to the submitted version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

This is a review paper, no new data were created.

Acknowledgments

We are very grateful to Dr David C. Kilpatrick for critical reading of the manuscript and helpful discussion.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Casals, C.; Garcia-Fojeda, B.; Minutti, C.M. Soluble defense collagens: sweeping up immune threats. Mol. Immunol. 2019, 112, 291–304. [Google Scholar] [CrossRef] [PubMed]
  2. Cedzyński, M.; Świerzko, A.S. Collectins and ficolins in neonatal health and disease. Front. Immunol. 2023, 14, 1328658. [Google Scholar] [CrossRef] [PubMed]
  3. Silveyra, P.; Floros, J. Genetic variant associations of human SP-A and SP-D with acute and chronic lung injury. Front. Biosci. 2012, 17, 407–429. [Google Scholar] [CrossRef] [PubMed]
  4. Vieira, F.; Kung, J.W.; Bhatti, F. Structure, genetics and function of the pulmonary associated surfactant proteins A and D: The extra-pulmonary role of these C type lectins. Ann. Anat. 2017, 211, 184–201. [Google Scholar] [CrossRef] [PubMed]
  5. Silveyra, P.; Floros, J. Genetic complexity of the human surfactant-associated proteins SP-A1 and SP-A2. Genes. 2013, 531, 126–132. [Google Scholar] [CrossRef] [PubMed]
  6. Floros, J.; Thorenoor, N.; Tsotakos, N.; Phelps, D.S. Human surfactant protein SP-A1 and SP-A2 variants differentially affect the alveolar microenvironment, surfactant structure, regulation and function of the alveolar macrophage, and animal and human survival under various conditions. Front Immunol. 2021, 12, 681639. [Google Scholar] [CrossRef]
  7. McCormack, F.X. Structure, processing and properties of surfactant protein A. Biochim. Biophys. Acta. 1998, 1408, 109–131. [Google Scholar] [CrossRef] [PubMed]
  8. Jakel, A.; Qaseem, A.S.; Kishore, U.; Sim, R.B. Ligands and receptors of lung surfactant proteins SP-A and SP-D. Front. Biosci. 2013, 18, 1129-1140. [CrossRef]
  9. Heidinger, K.; Konig, I.R.; Bohnert, A.; Kleinsteiber, A.; Hilgendorff, A.; Gortner, L,; Ziegler, A. ; Chakraborty, T.; Bein, G. Polymorphisms in the human surfactant protein-D (SFTPD) gene: strong evidence that serum levels of surfactant protein-D (SP-D) are genetically influenced. Immunogenetics. 2005, 57, 1–7. [Google Scholar] [CrossRef] [PubMed]
  10. Sorensen, G.L.; Hjelmborg, J.v.B.; Kyvik, K.O.; Fenger, M.; Hoj, A.; Bendixen, C.; Sorensen, T.I.; Holmskov, U. Genetic and environmental influences of surfactant protein D serum levels. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290, L1010–L1017. [Google Scholar] [CrossRef]
  11. Haagsman, H.P.; Diemel, R.V. Surfactant-associated proteins: functions and structural variations. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2001, 129, 91–108. [Google Scholar] [CrossRef]
  12. Kishore, U.; Greenhough, T.J.; Waters, P.; Shrive, A.K.; Ghai, R.; Kamran, M.F.; Bernal, A.L.; Reid, K.B.; Madan, T.; Chakraborty, T. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol. Immunol. 2006, 43, 1293–1315. [Google Scholar] [CrossRef] [PubMed]
  13. Ujma, S.; Horsnell, W.G.C.; Katz, A.A.; Clark, H.W.; Schafer, G. Non-pulmonary immune functions of surfactant proteins A and D. J. Innate Immun. 2017, 9, 3–11. [Google Scholar] [CrossRef] [PubMed]
  14. Nayak, A.; Dodagatta-Marri, E.; Tsolaki, A.G.; Kishore, U. An insight into the diverse roles of surfactant proteins SP-A and SP-D in innate and adaptive immunity. Front. Immunol. 2012, 3, 131. [Google Scholar] [CrossRef] [PubMed]
  15. Siegel, R.L.; Giaquinto, A.N.; Jemal, A. Cancer statistics, 2024. CA: Cancer J. Clin. 2024, 74, 12-49. [CrossRef]
  16. Kratzer, T.B.; Bandi, P.; Freedman, N.D.; Smith, R.A.; Travis, W.D.; Jemal, A.; Siegel, R.L. Lung cancer statistics, 2023. Cancer. 2024, 130, 1330–1348. [Google Scholar] [CrossRef] [PubMed]
  17. Zappa, C.; Mousa, S.A. Non-small lung cancer: current treatment and future advances. Trans. Lung Cancer Res. 2016, 5, 288–300. [Google Scholar] [CrossRef] [PubMed]
  18. Goto, H.; Mitsuhashi, A.; Nishyoka, Y. Role of surfactant protein A in non-infectious lung diseases. J. Med. Invest. 2014, 61, 1–6. [Google Scholar] [CrossRef]
  19. Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024, 74, 229–263. [Google Scholar] [CrossRef] [PubMed]
  20. Yamamoto, O.; Takahashi, H.; Hirasawa, M.; Chiba, H.; Shiratori, M,; Kuroki, Y.; Abe, S. Surfactant protein gene expressions for detection of lung carcinoma cells in peripheral blood. Resp. Med. 2005, 99, 1164-1174. [CrossRef]
  21. Mitsuhashi, A.; Goto, H.; Kuramoto, T.; Tabata, S.; Yukishige, S.; Abe, S.; Hanibuchi, M.; Kakiuchi, S.; Saijo, A.; Aono, Y.; Uehara, H.; Yano, S.; Ledford, J.G.; Sone, S.; Nishioka, Y. Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages. Am. J. Pathol. 2013, 182, 1843–1853. [Google Scholar] [CrossRef] [PubMed]
  22. Kaczmarek, M.; Lagiedo, M. , Masztalerz, A.; Kozłowska, M.; Nowicka, A.; Brajer, B.; Batura-Gabryel, H.; Sikora, J. Concentrations of SP-A and HSP70 are associated with polarization of macrophages in pleural effusions of non-small cell lung cancer. Immunobiology. 2018; 223, 200–209. [Google Scholar] [CrossRef]
  23. Shijubo, N.; Tsutahara, S.; Hirasawa, M. , Takahashi H.; Honda, A.; Suzuki, E.; Kuroki, Y.; Akino, T. Pulmonary surfactant protein A in pleural effusions. Cancer. 1992, 69, 2905–2909. [Google Scholar] [CrossRef]
  24. Shijubo, N.; Honda, Y.; Fujishima, T.; Takahashi, H.; Kodama, T.; Kuroki, Y.; Akino, T.; Abe, S. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma. Eur. Respir. J. 1995, 8, 403–406. [Google Scholar] [CrossRef]
  25. Takezawa, C.; Takahashi, H.; Fujishima, T.; Shiratori, M.; Morita, Y.; Sano, H.; Kuroki, Y.; Abe, S. Assessment of differentiation in adenocarcinoma cells from pleural effusion by peripheral airway cell markers and their diagnostic values. Lung Cancer. 2002, 38, 273–281. [Google Scholar] [CrossRef]
  26. Linnoilla, R.I.; Mulshine, J.L.; Steiberg, S.M.; Gazdar, A.F. Expression of surfactant-associated protein in non-small-cell lung cancer: a discriminant between biologic subsets. J. Natl. Cancer Inst. Monogr. 1992, 13, 61–66. [Google Scholar]
  27. Tsutahara, S.; Shijubo, N.; Hirasawa, M.; Honda, Y.; Satoh, M.; Kuroki, Y,; Akino, T. Lung adenocarcinoma with type II pneumocyte characteristics. Eur. Resp. J. 1993, 6, 135–137. [Google Scholar] [CrossRef]
  28. Mizutani, Y.; Nakajima, T.; Morinaga, S.; Gotoh, M.; Shimosato, Y.; Akino, T.; Suzuki, A. Immunohistochemical localization of pulmonary surfactant apoproteins in various lung tumors. Special reference to nonmucus producing lung adenocarcinomas. Cancer. 1988, 61, 532–537. [Google Scholar] [CrossRef] [PubMed]
  29. Noguchi, T.; Nakajima, T.; Hirohashi, S.; Akiba, T.; Shimosato, Y. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, amti-Lewis-a, and anti-Tn antibodies. Hum. Pathol. 1989, 20, 53–57. [Google Scholar] [CrossRef] [PubMed]
  30. Zamecnik, J.; Kodet, R. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas; a study of 109 cases. Virchows Arch. 2002, 440, 353–361. [Google Scholar] [CrossRef] [PubMed]
  31. Tsutsumida, H.; Goto, M.; Kitajima, S.; Kubota, I.; Hirotsu, Y.; Yonezawa, S. Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma. Histopathology. 2004, 44, 147–155. [Google Scholar] [CrossRef]
  32. Suzuki, A.; Shijubo, N.; Yamada, G.; Ichimiya, S.; Satoh, M.; Abe, S.; Sato, N. Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol. Res. Pract. 2005, 201, 579–586. [Google Scholar] [CrossRef] [PubMed]
  33. Yang, M.; Nonaka, D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod. Pathol. 2010, 23, 654–661. [Google Scholar] [CrossRef]
  34. Liu, J.; Li, X.Y.; Zhao, Y.Q.; Liu, R.Q.; Zhang, J.B.; Ma, J.; Chen, L.J.; Hu, X.F. Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: relationship between histologic subtypes, TIFF-1/SP-A expressions and EGFR mutations. Pathol. Res. Pract. 2014, 210, 176–181. [Google Scholar] [CrossRef]
  35. Sin, D.D.; Man, S.F.P.; McWilliams, A.; Lam, S. Surfactant protein D and bronchial dysplasia in smokers at high risk of lung cancer. Chest. 2008, 134, 582–588. [Google Scholar] [CrossRef]
  36. Yamaguchi, H.; Soda, H.; Nakamura, Y.; Takasu, M.; Tomonaga, N.; Nakano, H.; Doi, S.; Nakatomi, K.; Nagashima, S.; Takatani, H.; Fukuda, M.; Hayashi, T.; Tsukamoto, K.; Kohno, S. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 2011, 67, 331–338. [Google Scholar] [CrossRef]
  37. Umeda, Y.; Hasegawa, Y.; Otsuka, M.; Ariki, S.; Takamiya, R.; Saito, A.; Uehara, Y.; Saijo, H.; Kuronuma, K.; Chiba, H.; Ohnishi, H.; Sakuma, Y,; Takahashi, H.; Kuroki, Y.; Takahashi, M. Surfactant protein D inhibits activation of non-small lung cancer-associated mutant EGFR and affects clinical outcomes of patients. Oncogene. 2017, 36, 6432-6445. [CrossRef]
  38. Sato, H.; Ito, F.; Hasegawa, K.; Saga, R.; Hosokawa, Y.; Tanaka, M.; Aoki, M. Identification of novel prognostic factors focused on clinical outcomes in patients with non-small cell lung cancer after stereotactic body radiotherapy. Oncol. Lett. 2022, 23, 79. [Google Scholar] [CrossRef]
  39. Takahashi, H.; Imai, Y.; Fujishima, T.; Shiratori, M.; Murakami, S.; Chiba, H.; Kon, H.; Kuroki, Y.; Abe, S. Diagnostic significance of surfactant proteins A and D in sera from patients with radiation pneumonitis. Eur. Resp. J. 2001, 17, 481–487. [Google Scholar] [CrossRef]
  40. Shiels, M.S.; Chaturvedi, A.K.; Katki, H.A.; Gochuico, B.R.; Caporaso, N.E.; Engels, E.A. Circulating markers of interstitial lung disease and subsequent risk of lung cancer. Cancer Epidemiol. Biomarkers Prev. 2011, 20, 2262–2272. [Google Scholar] [CrossRef]
  41. Hasegawa, Y.; Takahashi, M.; Ariki, S.; Asakawa, D.; Tajiri, M.; Wada, Y.; Yamaguchi, Y.; Nishitani, C.; Takamiya, R.; Saito, A.; Uehara, Y.; Hashimoto, J.; Kurimura, Y.; Takahashi, H.; Kuroki, Y. Surfactant protein D suppresses lung cancer progression by down-regulation of epidermal growth factor signaling. Oncogene. 2015, 34, 838–845. [Google Scholar] [CrossRef]
  42. Hasegawa, Y.; Takahashi, M.; Ariki, S.; Saito, A.; Uehara, Y.; Takamiya, R.; Kuronuma, K.; Chiba, H.; Sakuma, Y.; Takahashi, H.; Kuroki, Y. Surfactant protein A down-regulates epidermal growth factor receptor by mechanisms different from those of surfactant protein D. J. Biol. Chem. 2017, 292, 18565–18576. [Google Scholar] [CrossRef]
  43. Broers, J.L.; Jensen, S.M.; Travis, W.D.; Pass, H.; Whitsett, J.A.; Singh, G.; Katyal, S.L.; Gazdar, A.F.; Minna, J.D.; Linnoila, R.I. Expression of surfactant-associated protein A and Clara cell 10 kilodalton mRNA in neoplastic and non-neoplastic human lung tissue as detected by in situ hybridization. Lab. Invest. 1992, 66, 337–346. [Google Scholar]
  44. Takahashi, H.; Kuroki, Y.; Honda, Y.; Shijubo, N.; Hirasawa, M.; Fujishima, T.; Akino, T.; Abe, S. Lipid analysis and surfactant-associated protein expression in lung adenocarcinoma cells from pleural effusion. Respiration. 1996, 63, 390–396. [Google Scholar] [CrossRef] [PubMed]
  45. Betz, G.; Papadopoulos, T.; Buchwald, J.; Dammrich, J.; Muller-Hermelink, H.K. Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarcinomas and other non-small lung carcinomas: detection by reverse transcriptase-polymerase chain reaction. Cancer Res. 1995, 55, 4283–4286. [Google Scholar] [PubMed]
  46. Wang, Y.; Kuan, P.J.; Xing, C.; Cronkhite, J.T.; Torres, F.; Rosenblatt, R.L.; DiMaio, J.M.; Kinch, L.N.; Grishin, N.V. , Garcia, C.K. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am. J. Hum. Genet. 2009, 84, 52–59. [Google Scholar] [CrossRef] [PubMed]
  47. Nathan, N.; Giraud, V.; Picard, C.; Nunes, H.; Dastot-Le Moal, F.; Copin, B.; Galeron, L.; De Ligniville, A.; Kuziner, N.; Reynaud-Gaubert, M.; Valeyre, D.; Couderc, J.-L.; Chinet, T.; Borie, R.; Crestani, B.; Simansour, M.; Nau, V.; Tissier, S.; Duquesnoy, P.; Mansour-Hendili, L.; Legendre, M.; Kannengiesser, C.; Coulomb-L’Hermine, A.; Gouya, L.; Amselem, S.; Clement, A. Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. Hum. Mol. Genet. 2016, 25, 1457–1467. [Google Scholar] [CrossRef]
  48. Legendre, M.; Butt, A.; Borie, R.; Debray, M.-P.; Bouvry, D.; Filhol-Blin, E.; Desroziers, T.; Nau, V.; Copin, B.; Dastot-Le Moal, F.; Hery, M.; Duquesnoy, P.; Allou, N.; Bergeron, A.; Bermudez, J.; Cazes, A.; Chene, A.-L.; Cottin, V.; Crestani, B.; Dalphin, J.-C.; Dombret, C.; Doray, B.; Dupin, C.; Giraud, V.; Gondouin, A.; Gouya, L.; Israel-Biet, D.; Kannengiesser, C.; Le Borgne, A.; Leroy, S.; Longchampt, E.; Lorillon, G.; Nunez, H.; Picard, C.; Reynaud-Gaubert, M.; Traclet, J.; de Vuyst, P.; Coulomb-L’Hermine, A.; Clement, A.; Amselem, S.; Nathan, N. Functional assessment and phenotypic heterogeneity of SFTPA1 and SFTPA2 mutations in interstitial lung diseases and lung cancer. Eur. Respir. J. 2020, 56, 2002806. [Google Scholar] [CrossRef]
  49. Ishii, T.; Hagiwara, K.; Ikeda, S.; Arai, T.; Mieno, M.N.; Kumasaka, T.; Maramatsu, M.; Sawabe, M.; Gemma, A.; Kida, K. Association between genetic variations in surfactant protein D and emphysema, interstitial pneumonia, and lung cancer in a Japanese population. COPD. 2012, 9, 409–416. [Google Scholar] [CrossRef]
  50. Wei, X.; Wang, C.; Feng, H.; Li, B.; Jiang, P.; Zhu, D.; Zhang, S.; Jin, T.; Meng, Y. Effects of ALOX5, IL6R and SFTPD gene polymorphisms on the risk of lung cancer: A case-control study in China. Int. Immunopharmacol. 2020, 79, 106155. [Google Scholar] [CrossRef] [PubMed]
  51. Grageda, M.; Silveyra, P.; Thomas, N.J.; DiAngelo, S.L.; Floros, J. DNA methylation profile and expression of surfactant protein A2 gene in lung cancer. Exp. Lung Res. 2015, 41, 93–102. [Google Scholar] [CrossRef]
  52. Lin, Z.; Thomas, N.J.; Bibikova, M.; Seifart, C.; Wang, Y.; Guo, X.; Wang, G.; Vollmer, E.; Goldmann, T.; Garcia, E.W.; Zhou, L.; Fan, J.-B.; Floros, J. DNA methylation markers of surfactant proteins in lung cancer. Int. J. Oncol. 2007, 31, 181–191. [Google Scholar] [CrossRef] [PubMed]
  53. Jiang, F.; Yin, Z.; Caraway, N.P.; Li, R.; Katz, R.L. Genomic profiles in stage I primary non small lung cancer using comparative genomic hybridization analysis of cDNA microarrays. Neoplasia. 2004, 6, 623–635. [Google Scholar] [CrossRef]
  54. Jiang, F.; Caraway, N.P., Nebioyu Bekele, B.; Zhang, H.Z.; Kahnna, A.; Wang, H.; Li, R.; Fernandez, R.L.; Zaidi, T.M.; Johnston, D.A.; Katz, R.L. Surfactant protein A gene deletion and prognosis for patients with stage I non-small cell lung cancer. Clin. Cancer Res. 2005, 11, 5417-5427. [CrossRef]
  55. Li, Z.; Fan, Y.; Ma, Y.; Meng, N.; Li, D.; Wang, D.; Lian, J.; Hu, C. Identification of crucial genes and signaling pathways in alectinib-resistant lung adenocarcinoma using bioinformatic analysis. Mol. Biotechnol. 2023, in press. [Google Scholar] [CrossRef] [PubMed]
  56. Mangogna, A.; Belmonte, B.; Agostinis, C.; Ricci, G.; Gulino, A.; Ferrara, I.; Zanconati, F.; Tipodo, C.; Romano, F.; Kishore, U.; Bulla, R. Pathological significance and prognostic value of surfactant protein D in cancer. Front. Immunol. 2018, 9, 1748. [Google Scholar] [CrossRef]
  57. Lu, J. Collectins: collectors of microorganisms for the innate immune system. Bioessays. 1997, 19, 509–518. [Google Scholar] [CrossRef]
  58. Madsen, J.; Kliem, A.; Tornoe, I.; Skjodt, K.; Koch, C.; Holmskov, U. Localization of lung surfactant protein D on mucosal surfaces in human tissues. J. Immunol. 2000, 164, 5866–5870. [Google Scholar] [CrossRef]
  59. Madsen, J.; Tornoe, I.; Nielsen, O.; Koch, C.; Steinhilber, W.; Holmskov, U. Expression and localization of lung surfactant protein A in human tissues. Am. J. Respir. Cell. Mol. Biol. 2003, 29, 591–597. [Google Scholar] [CrossRef]
  60. Oberley, R.E.; Goss, K.L.; Dahmoush, L.; Ault, K.A.; Crouch, E.C.; Snyder, J.M. A role for surfactant protein D in innate immunity of the human prostate. Prostate. 2005, 65, 241–251. [Google Scholar] [CrossRef]
  61. Herias, M.V.; Hogenkamp, A.; van Asten, A.J.A.M.; Tersteeg, M.H.G.; van Ejik, M.; Haagsman, H.P. Expression sites of the collectin SP-D suggest its importance in first line host defence: power of combining in situ hybridisation, RT-PCR and immunohistochemistry. Mol. Immunol. 2007, 44, 3324–3332. [Google Scholar] [CrossRef] [PubMed]
  62. Beileke, S.; Claassen, H.; Wagner, W.; Matthies, C.; Ruf, C.; Hartmann, A.; Garrels, F.; Paulsen, F.; Schicht, M.; Brauer, L. Expression and localization of lung surfactant proteins in human testis. PLoS One. 2015, 10, e0143058. [Google Scholar] [CrossRef] [PubMed]
  63. Kankavi, O.; Baykara, M.; Karanis, M.I.E.; Bassorgun, C.I.; Ergin, H.; Ciftcioglu, M.A. Evidence of surfactant protein A and D expression decrement and their localizations in human prostate adenocarcinomas. Ren. Fail. 2014, 36, 258–265. [Google Scholar] [CrossRef] [PubMed]
  64. Thakur, G.; Prakash, G.; Murthy, V.; Sable, N.; Menon, S.; Alrokayan, S.H.; Khan, H.A.; Murugaiah, V.; Bakshi, G.; Kishore, U.; Madan, T. Human SP-D acts as immune surveillance molecule against androgen-responsive and androgen-resistant prostate cancer cells. Front. Oncol. 2019, 9, 565. [Google Scholar] [CrossRef]
  65. Ganguly, K.; Kishore, U.; Metkari, S.M.; Madan, T. Immunomodulatory role of surfactant protein-D in a transgenic adenocarcinoma of mouse prostate (TRAMP) model. Front. Immunol. 2022, 13, 930449. [Google Scholar] [CrossRef]
  66. Thakur, G.; Sathe, G.; Kundu, I.; Biswas, B,; Gautam, P.; Alkahtani, S.; Idicula-Thomas, S.; Sirdeshmukh, R.; Kishore, U.; Madan, T. Membrane interactome of a recombinant fragment of human surfactant protein D reveals GRP78 as a novel binding partner in PC3, a metastatic prostate cancer cell line. Front. Immunol. 2021, 11, 600660. [CrossRef]
  67. Murugaiah, V.; Agostinis, C.; Varghese, P.M.; Belmonte, B.; Vieni, S.; Alaql, F.A.; Alrokayan, S.H.; Khan, H.A.; Kaur, A.; Roberts, T.; Madan, T.; Bulla, R.; Kishore, U. Hyaluronic acid present in the tumour microenvironment can negate the pro-apoptotic effect of a recombinant fragment of human surfactant protein D on breast cancer cells. Front. Immunol. 2020, 11, 1171. [Google Scholar] [CrossRef]
  68. Oberley, R.E.; Goss, K.L.; Ault, K.A.; Crouch, E.C.; Snyder, J.M. Surfactant protein D is present in the human female reproductive tract and inhibits Chlamydia trachomatis infection. Mol. Hum. Reprod. 2004, 10, 861–870. [Google Scholar] [CrossRef]
  69. Kumar, J.; Murugaiah, V.; Sotiriadis, G.; Kaur, A.; Jeyaneethi, J.; Sturniolo, I.; Alhamian, F.S.; Chatterjee, J.; Hall, M.; Kishore, U.; Karteris, E. Surfactant protein D as a potential biomarker and therapeutic target in ovarian cancer. Front. Oncol. 2019, 9, 542. [Google Scholar] [CrossRef] [PubMed]
  70. Alshaya, D.S.; Jalal, A.S.; Alburae, N.A.; Aljarba, N.H.; Murugaiah, V.; Kishore, U.; Al-Qahtani, A.A. Carbon nanotube-coated recombinant human surfactant protein D reduces cell viability in an ovarian cancer cell line, SKOV3, and modulates mTOR pathway and pro-inflammatory cytokine response. J. King Saud Univ. Sci. 2022, 34, 101851. [Google Scholar] [CrossRef]
  71. Tajima, Y.; Tsuruta, M.; Hasegawa, H.; Okabayashi, K.; Ishida, T.; Yahagi, M. , Makino, A.; Koishikawa, K.; Akimoto, S.; Sin, D.D.; Kitagawa, Y. Association of surfactant protein D with pulmonary metastases from colon cancer. Oncol. Lett. 2020, 20, 322. [Google Scholar] [CrossRef] [PubMed]
  72. Kaur, A.; Riaz, M.S.; Murugaiah, V.; Varghese, P.M.; Singh, S.K.; Kishore, U. A recombinant fragment of human surfactant protein D induces apoptosis in pancreatic cancer cell lines via Fas-mediated pathway. Front. Immunol. 2018, 9, 1126. [Google Scholar] [CrossRef] [PubMed]
  73. Kaur, A.; Riaz, M.S.; Singh, S.K.; Kishore, U. Human surfactant protein D suppresses epithelial-to-mesenchymal transition in pancreatic cancer cells by downregulating TGF-β. Front. Immunol. 2018, 9, 1844. [Google Scholar] [CrossRef] [PubMed]
  74. Griese, M.; Neumann, M.; von Bredow, T.; Schmidt, R.; Ratjen, F. Surfactant in children with malignancies, immunosuppression, fever and pulmonary infiltrates. Eur. Resp. J. 2002, 20, 1284–1291. [Google Scholar] [CrossRef] [PubMed]
  75. Mahajan, L.; Pandit, H.; Madan, T.; Gautam, P.; Yadav, A.K.; Warke, H.; Sundaram, C.S.; Sirdeshmukh, R.; Sarma, P.U.; Kishore, U.; Surolia, A. Human surfactant protein D alters oxidative stress and HMGA1 expression to induce p53 apoptotic pathway in eosinophilic leukemic cell line. PLoS One. 2013, 8, e85046. [Google Scholar] [CrossRef]
  76. Mahajan, L.; Gautam, P.; Dodagatta-Marri, E.; Madan, T.; Kishore, U. Surfactant protein SP-D modulates activity of immune cells: proteomic profiling of its interaction with eosinophilic cells. Expert Rev. Proteomics. 2014, 11, 355–369. [Google Scholar] [CrossRef]
Preprints 113383 g001aPreprints 113383 g001b
Figure 1. Organisation of SFTPA1/2 and SFTPD genes and domain organisation of polypeptide chains of SP-A and SP-D (A). Schematic structure of single chains, basic triplet subunits and oligomers of SP-A and SP-D (B).
Figure 1. Organisation of SFTPA1/2 and SFTPD genes and domain organisation of polypeptide chains of SP-A and SP-D (A). Schematic structure of single chains, basic triplet subunits and oligomers of SP-A and SP-D (B).
Preprints 113383 g001aPreprints 113383 g001b
Preprints 113383 g002
Figure 2. Polymorphic sites distinguishing between SFTPA1 and SFTPA2 genes (A), variants of SFTPA1 gene (B) and SFTPA2 (C) gene. Green braces mark SFTPA1 or SFTPA2 variants corresponding to mature SP-A1 or SP-A2 proteins with identical sequences.
Figure 2. Polymorphic sites distinguishing between SFTPA1 and SFTPA2 genes (A), variants of SFTPA1 gene (B) and SFTPA2 (C) gene. Green braces mark SFTPA1 or SFTPA2 variants corresponding to mature SP-A1 or SP-A2 proteins with identical sequences.
Preprints 113383 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Downloads

130

Views

68

Comments

0

Subscription

Notify me about updates to this article or when a peer-reviewed version is published.

Email

Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2025 MDPI (Basel, Switzerland) unless otherwise stated